Expertise in
10
conditions

Dr. Latoya J. Perry

Oncology
Beacon Medical Group Inc.
100 Navarre Pl Ste 4470, 
South Bend, IN 
Accepting New Patients
Expertise in
10
conditions
Beacon Medical Group Inc.
100 Navarre Pl Ste 4470, 
South Bend, IN 

Overview

Latoya Perry is an Oncologist practicing medicine in South Bend, Indiana.

Dr. Perry is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Vulvar Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Lymphadenectomy, and Bladder Reconstruction.

She is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 13 clinical trials. Dr. Perry is currently accepting new patients.

Graduate Institution

Medical College Of Wisconsin

Specialties

Oncology

Licenses

Obstetrics & Gynecology in IN

Hospital Affiliations

Elkhart General Hospital
Memorial Hospital Of South Bend
Saint Joseph Regional Medical Center - Plymouth
Franciscan Health Michigan City

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Beacon Medical Group Inc.
100 Navarre Pl Ste 4470, South Bend, IN 46601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Unknown
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
View 9 Less Clinical Trials

5 Total Publications

Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.
Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 21, 2014
Similar Doctors
Expertise in
64
conditions
Expertise in
64
conditions
Referral may be required
Before you request

Corewell Health Lakeland Hospitals Cancer Care Specialists Niles

42 North Saint Joseph Avenue, Suite 304, 
Niles, MI 
 (11.3 miles away)
269-428-4411
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edmund Paloyan is an Oncologist practicing medicine in Niles, Michigan. Dr. Paloyan is highly rated in 64 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Familial Colorectal Cancer, Breast Cancer, and Colorectal Cancer. Dr. Paloyan is board certified in American Board Of Internal Medicine. Dr. Paloyan is currently accepting new patients.

Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Ascension Borgess-Lee Hospital

420 W High St, 
Dowagiac, MI 
 (22.7 miles away)
269-783-3045
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Muhammad Hameed is an Oncologist practicing medicine in Dowagiac, Michigan. Dr. Hameed is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Teratoma of the Mediastinum. Dr. Hameed is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Office

621 Memorial Dr Ste 100, 
South Bend, IN 
 (0.1 miles away)
574-647-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nonyem Onujiogu is an Oncologist practicing medicine in South Bend, Indiana. Dr. Onujiogu is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Cervical Cancer, Endometrial Cancer, and Vulvar Cancer. Dr. Onujiogu is currently accepting new patients.

Frequently Asked Questions about Dr. Latoya J. Perry

How do I make an appointment with Dr. Latoya J. Perry?

You can book an appointment with Dr. Latoya J. Perry by calling their office at 574-647-4230. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Latoya J. Perry a top-rated expert for Vulvar Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Latoya J. Perry is classified as an Advanced expert for Vulvar Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Latoya J. Perry specialize in?

While Dr. Latoya J. Perry is a Oncology, they have specific expertise in Vulvar Cancer, Malignant Mixed Mullerian Tumor, and Endometrial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Latoya J. Perry participate in research or clinical trials?

Yes. Dr. Latoya J. Perry has published 5 articles and abstracts on conditions like Vulvar Cancer. You can view a list of Dr. Latoya J. Perry's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Latoya J. Perry accept my insurance?

Dr. Latoya J. Perry accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 574-647-4230 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Perry's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile